Objectives: Fetal atrioventricular block (AVB) occurs in 2-4% of anti-Ro antibody positive pregnancies. The purpose of our study was to test the feasibility and report the outcomes of anti-Ro pregnancies surveilled with 2x/day home fetal heart rhythm (FHR) monitoring as an adjunct to standard serial echocardiography. Methods: This was a prospective multicentre observational study. Eligible pregnant women at 16-18 were recruited from 16 international centres. Mothers monitored FHR 2x/day with a commercially available Doppler device in addition to undergoing weekly or every other week surveillance fetal echocardiograms until 26 weeks. If an abnormal FHR was detected, a diagnostic echocardiogram was performed. We measured the cardiac cycle length and AV interval; we assessed rhythm, atrioventricular valve function any and signs of endocardial fibroelastosis (EFE) or effusions on all echocardiograms. Study end-point was rhythm on postnatal 12-lead electrocardiogram. Results: We compiled data on 1755 echocardiograms from 271 fetuses. Study retention rate was 87%. Effusions, EFE, and AV valve insufficiency were rare. Four fetuses had prolonged AV intervals ≥ +2 z-scores; one was treated and none progressed to 3
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• AVB.
Twenty-four mothers heard an abnormal FHR: 11 had benign arrhythmias, 10 were normal, 1 had intermittent Wenkebach 2 Objectives: To study the prenatal prognostic markers of short and long-term outcomes in fetuses affected with immune complete atrioventricular block (ICAVB). Methods: Retrospective study of cases diagnosed during 2 nd trimester with grade III ICAVB, defined by complete atrioventricular dissociation, with positive circulating antibodies (SSA/SSB) and normal cardiac anatomy. Echocardiography was performed at least monthly after diagnosis, and weekly from 28 weeks. Delivery was scheduled around 36 weeks. A pacemaker (PM) was placed shortly after birth in cases of bradycardia <50 bpm or hemodynamic failure. Pediatric follow-up was >6 months in all cases: time to event methods were used to analyse the impact of fetal heart rate (FHR) on the PM timing. Results: In the 44 cases included, there were 5 (11%) perinatal deaths, 2 of which had developed hydrops prenatally. A PM was placed in 33 (75%) cases: 18/33 (54,5%) within the first week (early PM) and 15 (45,5%) >1 week (late PM). 6 cases were alive and well without PM at the end of the study. No difference in outcome was found between AVB treated in utero versus the no-treatment group. Last FHR was significantly correlated with the timing of PM (P<0.001). The figure shows the Kaplan Meier curves for groups of prenatal HR. The hazard ratio of FHR for postnatal PM was 0.9 per bpm (Cox model, P<0.001). Conclusions: In ICAVB, prenatal FHR is significantly correlated to the timing of postnatal PM implantation, both in the immediate neonatal period and in the long term.
